-5%
Brigacent 90mg Tablet is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic Non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.
Brigatinib (Therapeutic Class: Cytotoxic Chemotherapy)
- Form: Tablet
- Administration: Oral (by mouth)
- Frequency: Once daily
- Timing: Around the same time every day
- Food: Can be taken with or without food
- Dosage: Follow your doctor’s prescription label instructions
- Swallowing: Swallow the tablets whole; do not chew or crush them.
